COVID‐19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BioFactors (Oxford) 2020-05, Vol.46 (3), p.306-308
1. Verfasser:	Theoharides, Theoharis C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin-Converting Enzyme 2 Antiviral Agents - therapeutic use Betacoronavirus - drug effects Betacoronavirus - pathogenicity Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - pathology Coronavirus Infections - virology COVID-19 Cytokine Release Syndrome - immunology Cytokine Release Syndrome - pathology Cytokine Release Syndrome - prevention & control Cytokine Release Syndrome - virology Humans Hypothesis Lung - drug effects Lung - immunology Lung - virology Luteolin - therapeutic use Mast Cells - drug effects Mast Cells - immunology Mast Cells - virology Pandemics Peptidyl-Dipeptidase A - genetics Peptidyl-Dipeptidase A - immunology Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - pathology Pneumonia, Viral - virology Quercetin - therapeutic use Renin-Angiotensin System - drug effects Renin-Angiotensin System - genetics Renin-Angiotensin System - immunology Research Design Respiratory System Agents - therapeutic use SARS-CoV-2 Severity of Illness Index Spike Glycoprotein, Coronavirus - antagonists & inhibitors Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!